Acquisitions and Divestitures - Consideration Paid For HRA Pharma (Details) $ in Millions, € in Billions	Apr. 29, 2022 EUR (€)	Apr. 29, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Assets Acquired:
Goodwill			$ 3,529.1	$ 3,490.4	$ 2,999.4
HRA Pharma
Business Acquisition [Line Items]
Purchase Price	€ 1.8	$ 1,945.6
Assets Acquired:
Cash and cash equivalents		44.2
Accounts receivable		78.1
Inventories		48.3
Prepaid expenses and other current assets		16.6
Property, plant and equipment		4.6
Operating lease assets		9.7
Goodwill		559.5
Total intangible assets		1,446.2
Deferred income taxes		12.4
Other non-current assets		0.8
Total assets		2,220.4
Liabilities assumed:
Accounts payable		43.4
Payroll and related taxes		16.1
Accrued customer programs		9.0
Other accrued liabilities		8.9
Accrued income taxes		0.5
Deferred income taxes		186.2
Other non-current liabilities		10.6
Total liabilities		274.7
Non-Controlling Interest		0.1
Net Assets Acquired		1,945.6
HRA Pharma | In-process research and development
Assets Acquired:
Total intangible assets		52.7
HRA Pharma | Trademarks and trade names
Assets Acquired:
Definite-lived intangible assets:		1,124.0
HRA Pharma | Developed product technology
Assets Acquired:
Definite-lived intangible assets:		185.1
HRA Pharma | Distribution networks
Assets Acquired:
Definite-lived intangible assets:		$ 84.4